Skip to main content

Table 2 Participants characteristics

From: A meta-analysis of the efficacy of allopurinol in reducing the incidence of myocardial infarction following coronary artery bypass grafting

Study n Mean Age Male (%) Mean EF (%) Mean NYHA Class Triple Vessel Disease (%) ≥1 anti-anginal medication (%) Previous MI (%) DM (%) Renal Disease (%) Prior use of Allopurinol
Emerit et al. (1988) 14 NR NR NR NR NR NR NR NR NR NR
Rashid et al. (1991) 90 62 76 > 50a 2.3 NR NR NR NRe NRe NR
Coghlan et al. (1994) 50 58 84 63 NRb 92 NRd 34 14 NR NR
Taggart et al. (1994) 20 60 100 53 NR NR NR NR NR 0 0
Castelli et al. (1995) 33 61 94 64 3 NR NR 79 NR NR NR
Gimpel et al. (1995) 22 59 77 NR NRc NR 100 50 NR NR NR
  1. EF ejection fraction, NYHA New York Heart Association, MI myocardial infarction, DM diabetes mellitus; NR, not reported
  2. The number of decimal places reported in the included studies varied. Data has been rounded up to whole where appropriate
  3. aEjection fraction > 50% in 71% of the allopurinol group and 67% of the control group
  4. bMean NYHA class not specified. 80% of (n) with NYHA class 3 or 4
  5. cMean NYHA class not specified. 100% of (n) with NYHA class 3 or 4
  6. dReports nitrate use in 10%, beta-blocker use in 46% and calcium channel blocker use in 44%
  7. ePrevalence of ‘other organ disease/dysfunction’ reported to be zero. It was unclear whether this included previous cerebrovascular disease, DM, renal disease and/or PAD